СУРУНКАЛИ ЮРАК ЕТИШМОВЧИЛИГИДА БУЙРАК ДИСФУНКЦИЯСИ КЕЧГАНДА ВИТАМИН Д, ЭЛЕКТРОЛИТЛАР АЛМАШИНУВИ ВА КОМПЛЕКС МУОЛАЖАЛАРНИНГ ТАЪСИРИ
Kalit so‘zlar:
сурункали юрак етишмовчилиги, буйрак дисфункцияси, Витамин Д, электролитларAbstrak
Мақолада сурункали юрак етишмовчилиги (СЮЕ) турли даражадаги буйрак дисфункцияси билан кечганда Витамин Д ва электролитлар динамикаси ҳамда комплекс давонинг минерал-гормонлар алмашинувига таъсири ўрганилди. 120 нафар бемор ҳКФТ бўйича уч гуруҳга ажратилди, 1- ва 2-гуруҳдаги 15 нафардан беморга стандарт давога қўшимча севеламер карбонат тавсия этилди. Буйрак фаолияти пасайиши билан Витамин Д (27,8; 34,7; 39,2 нг/мл) ва натрий камайди. Комплекс даво таъсирида Витамин Д ошди, альдостерон камайди; севеламер карбонат қўшилиши ҳКФТ <60 гуруҳда маркерлар динамикасига яққол ижобий таъсир кўрсатди.
##plugins.themes.default.displayStats.downloads##
Havolalar
1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention and Treatment of CKD–MBD. Kidney Int Suppl. 2017;7:1–59.
2. Evenepoel P, Wolf M. A balanced view of calcium and phosphate homeostasis in chronic kidney disease. Kidney Int. 2013;83:789–791.
3. Radloff J, Latic N, Pfeiffenberger U, et al. A phosphate and calcium-enriched diet promotes progression of 5/6-nephrectomy-induced chronic kidney disease in C57BL/6 mice. Sci Rep. 2021;11:14868.
4. Maeoka Y, Ferdaus MZ, Cornelius RJ, et al. Combined Kelch-like 3 and Cullin 3 degradation is a central mechanism in familial hyperkalemic hypertension in mice. J Am Soc Nephrol. 2022;33(3):584–600.
5. Hassanein M, Arrigain S, Schold JD, et al; CRIC Investigators. Dysnatremias, mortality and kidney failure in CKD: findings from the CRIC study. Kidney Med. 2022;4(12):100554.
6. Arzhan S, Lew SQ, Ing TS, Tzamaloukas AH, Unruh ML. Dysnatremias in chronic kidney disease: pathophysiology, manifestations and treatment. Front Med. 2021;8:769287.
7. Tang WHW, et al. Evaluation and management of kidney dysfunction in advanced heart failure: a scientific statement from the American Heart Association. Circulation. 2024;150(16):e280–e295.
8. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726.
9. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012;33(14):1787–1847.
10. Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol. 2013;75:503–533.
11. Kuro-o M. The Klotho proteins in health and disease. Nat Rev Nephrol. 2019;15(1):27–44.
12. Erben RG. Physiological actions of fibroblast growth factor-23. Front Endocrinol. 2018;9:267.
13. Fan Z, Wei X, Zhu X, et al. Correlation between soluble Klotho and chronic kidney disease–mineral and bone disorder in CKD: a meta-analysis. Sci Rep. 2024;14:4477.
14. Waziri B, Duarte R, Naicker S. Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD): current perspectives. Int J Nephrol Renovasc Dis. 2019;12:263–276.
15. Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143:1157–1172.
16. Беленков Ю.Н., Мареев В.Ю. Принципы рационального лечения сердечной недостаточности. — М.: Медиа Медика, 2006.
17. Абдуллаев Т.А. Хроническая сердечная недостаточность: современные аспекты диагностики и лечения. — Ташкент, 2017.
18. Нагаева Г.А. и др. Сердечно-сосудистая заболеваемость и смертность в Республике Узбекистан. — Ташкент, 2016.
